GT Medical Technologies fetches $45m Series C

• Funds from this round will support the expanded commercialization of therapy for patients with operable brain tumors
• In addition, the funding will support its clinical study plans
• Gilde Healthcare is a specialized healthcare investor managing over $2 billion across two fund strategies: venture & growth capital and private equity

GT Medical Technologies, Inc., a medical device company focused on improving the lives of patients with brain tumors, has raised $45 million in Series C financing.

Gilde Healthcare Partners with participation from existing institutional investors MVM Partners, MedTech Venture Partners, and BlueStone Venture Partners.

Funds from this round will support the expanded commercialization of therapy for patients with operable brain tumors. In addition, the funding will support its clinical study plans.

“Our focus is making state-of-the-art medical advancements like GammaTile more available to patients to address unmet clinical needs and ultimately improve the standard of care,” said Geoff Pardo, general partner, Gilde Healthcare Partners, in a statement. “It’s gratifying to know that we’re enabling GT Medical Technologies to improve the lives of more patients with brain tumors.”

Gilde Healthcare is a specialized healthcare investor managing over $2 billion across two fund strategies: venture & growth capital and private equity.

MVM has invested in high-growth healthcare businesses since 1997.